VRTX vs BMRN

For growth investors, BioMarin Pharmaceutical Inc.

(BMRN) is the stronger pick with 12. 9% revenue growth year-over-year, versus 9. 6% for Vertex Pharmaceuticals Incorporated (VRTX). Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 27. 9x trailing P/E (22. 3x forward), making it the more compelling value choice. Analysts rate Vertex Pharmaceuticals Incorporated (VRTX) a "Buy" — based on 56 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Vertex Pharmaceuticals Incorporated (VRTX) is the cheapest at 27.

9x versus BioMarin Pharmaceutical Inc. at 30. 3x. On forward P/E, BioMarin Pharmaceutical Inc. is actually cheaper at 12. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +100.

6%, compared to -30. 5% for BioMarin Pharmaceutical Inc. (BMRN). Over 10 years, the gap is even starker: VRTX returned +399. 9% versus BMRN's -32. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc.

(BMRN) is the lower-risk stock at 0. 65β versus Vertex Pharmaceuticals Incorporated's 0. 82β — meaning VRTX is approximately 26% more volatile than BMRN relative to the S&P 500. On balance sheet safety, BioMarin Pharmaceutical Inc. (BMRN) carries a lower debt/equity ratio of 11% versus 21% for Vertex Pharmaceuticals Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BioMarin Pharmaceutical Inc.

(BMRN) is pulling ahead at 12. 9% versus 9. 6% for Vertex Pharmaceuticals Incorporated (VRTX). On earnings-per-share growth, the picture is similar: Vertex Pharmaceuticals Incorporated grew EPS 836. 5% year-over-year, compared to -18. 6% for BioMarin Pharmaceutical Inc.. Over a 3-year CAGR, BMRN leads at 15. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus 10. 8% for BioMarin Pharmaceutical Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39. 4% versus 16. 6% for BMRN. At the gross margin level — before operating expenses — VRTX leads at 85. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, BioMarin Pharmaceutical Inc.

(BMRN) trades at 12. 7x forward P/E versus 22. 3x for Vertex Pharmaceuticals Incorporated — 9. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMRN: 64. 2% to $89. 64.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

82), +399. 9% 10Y return). Both have compounded well over 10 years (VRTX: +399. 9%, BMRN: -32. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.